STOCKHOLM, May 15, 2018 /PRNewswire/ --
Moberg Pharma AB's ("Company") Annual General Meeting took
place on Tuesday, May 15th, 2018 in
the Company´s premises in Bromma.
Adoption of the income statements and the balance
sheets
The Annual General Meeting (the "Meeting") approved the income
statements and the balance sheets for the fiscal year 2017.
The Meeting resolved, in accordance with the proposal of the
Board of Directors, that no dividend should be paid for the fiscal
year 2017.
The Meeting discharged the Board members and the Chief Executive
Officer from liability for the fiscal year 2017.
Board of Directors
In accordance with the
proposal of the Nomination Committee, the Meeting resolved that the
Board of Directors shall consist of five persons and no
deputies.
The Meeting resolved re-election of the Board Directors
Thomas Eklund (Chairman),
Geert Cauwenbergh, Sara Brandt and Mattias Klintemar, and election
of Anna Malm Bernsten as new member,
until the end of the next Annual General Meeting. Torbjörn Koivisto
and Thomas B. Thomsen have chosen,
after nine years and four years as Board Directors, to resign.
The Meeting resolved, in accordance with the proposal of the
Nomination Committee, that an aggregate fee to Board members of
SEK 1,220,000 shall be paid to the
Board Directors, of which SEK 360,000
to the Chairman and SEK 170,000 for
all other Board Directors elected by the Annual General Meeting. An
additional fee of SEK 90,000 shall be
paid to the members of the Remuneration Committee, SEK 45,000 to the chairman and SEK 22,500 to the other members (2). A fee of
SEK 90,000 shall be paid to the
members of the Audit and Finance Committee, SEK 45,000 to the chairman and SEK 22,500 to the other members (2).
Fees to the Auditors, for a period until the end of the next
Annual General Meeting, are to be paid as per approved
invoice.
Nomination Committee
The Meeting resolved, in
accordance with the proposal of the Nomination Committee, that the
Company shall have a Nomination Committee consisting of four
members. The Nomination Committee shall comprise one representative
of each of the three largest shareholders or owner groups in the
Company in terms of votes as per September
28, 2018, besides the Chairman of the Board of
Directors.
Principles for remuneration
The Meeting
resolved to approve the Board of Director's proposal for principles
of remuneration to senior executives in Moberg Pharma.
Implementation of LTI 2018
The Meeting also
resolved to approve the Board of Director's proposal to implement a
long-term incentive program, including transfer of up to 263 000
ordinary shares to the participants and other hedging arrangements
in respect of the program, including amendments of the articles of
association to be able to issue redeemable and convertible class C
shares, as well as authorization for the Board of Directors to
resolve on a directed issue and repurchase of up to 263 000 class C
shares.
Authorization to issue share
The Meeting
resolved, in accordance with the proposal of the Board of
Directors, to authorize the Board of Directors to, within the scope
of the articles of association, with or without deviation from the
shareholders' preferential right, on one or several occasions
during the period until the next Annual General Meeting, resolve to
increase the Company's share capital by issuing new shares in the
Company. The total number of shares issued in accordance with this
authorization may be equivalent to a maximum of 20 per cent of the
shares in the Company at the time of the 2018 Annual General
Meeting.
About this information
Moberg Pharma discloses
the information provided herein pursuant to the Securities Markets
Act and/or the Financial Instruments Trading Act. The information
was submitted for publication at 8:00 pm
(CET) on May 15th, 2018.
For additional information, please
contact:
Peter
Wolpert, CEO, telephone: +1-908-432-22-03 (US),
+46-70-735-71-35, e-mail: peter.wolpert@mobergpharma.se
Anna Ljung, CFO, telephone:
+46-707-66-60-30, e-mail: anna.ljung@mobergpharma.se
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/moberg-pharma/r/bulletin-from-moberg-pharma-s-agm-2018,c2521050
The following files are available for download:
http://mb.cision.com/Main/1662/2521050/841511.pdf
|
Bulletin from Moberg
Pharma’s AGM 2018
|
View original
content:http://www.prnewswire.com/news-releases/bulletin-from-moberg-pharmas-agm-2018-300648885.html
SOURCE Moberg Pharma